206 related articles for article (PubMed ID: 31215459)
1. Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models.
Fukami S; Tomioka D; Murakami Y; Honda T; Hatakeyama S
BMC Res Notes; 2019 Jun; 12(1):347. PubMed ID: 31215459
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.
Kurio N; Shimo T; Fukazawa T; Takaoka M; Okui T; Hassan NM; Honami T; Hatakeyama S; Ikeda M; Naomoto Y; Sasaki A
Exp Cell Res; 2011 May; 317(8):1134-46. PubMed ID: 21338601
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.
Liu TJ; LaFortune T; Honda T; Ohmori O; Hatakeyama S; Meyer T; Jackson D; de Groot J; Yung WK
Mol Cancer Ther; 2007 Apr; 6(4):1357-67. PubMed ID: 17431114
[TBL] [Abstract][Full Text] [Related]
4. TAE226, a dual inhibitor of focal adhesion kinase and insulin-like growth factor-I receptor, is effective for Ewing sarcoma.
Moritake H; Saito Y; Sawa D; Sameshima N; Yamada A; Kinoshita M; Kamimura S; Konomoto T; Nunoi H
Cancer Med; 2019 Dec; 8(18):7809-7821. PubMed ID: 31692287
[TBL] [Abstract][Full Text] [Related]
5. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.
Watanabe N; Takaoka M; Sakurama K; Tomono Y; Hatakeyama S; Ohmori O; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Beer DG; Nagatsuka H; Tanaka N; Naomoto Y
Clin Cancer Res; 2008 Jul; 14(14):4631-9. PubMed ID: 18628478
[TBL] [Abstract][Full Text] [Related]
6. TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells.
Wang ZG; Fukazawa T; Nishikawa T; Watanabe N; Sakurama K; Motoki T; Takaoka M; Hatakeyama S; Omori O; Ohara T; Tanabe S; Fujiwara Y; Shirakawa Y; Yamatsuji T; Tanaka N; Naomoto Y
Oncol Rep; 2008 Dec; 20(6):1473-7. PubMed ID: 19020730
[TBL] [Abstract][Full Text] [Related]
7. TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
Otani H; Yamamoto H; Takaoka M; Sakaguchi M; Soh J; Jida M; Ueno T; Kubo T; Asano H; Tsukuda K; Kiura K; Hatakeyama S; Kawahara E; Naomoto Y; Miyoshi S; Toyooka S
PLoS One; 2015; 10(6):e0129838. PubMed ID: 26090892
[TBL] [Abstract][Full Text] [Related]
8. TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis.
Schultze A; Decker S; Otten J; Horst AK; Vohwinkel G; Schuch G; Bokemeyer C; Loges S; Fiedler W
Invest New Drugs; 2010 Dec; 28(6):825-33. PubMed ID: 19784551
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.
Halder J; Lin YG; Merritt WM; Spannuth WA; Nick AM; Honda T; Kamat AA; Han LY; Kim TJ; Lu C; Tari AM; Bornmann W; Fernandez A; Lopez-Berestein G; Sood AK
Cancer Res; 2007 Nov; 67(22):10976-83. PubMed ID: 18006843
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma.
Kurio N; Shimo T; Fukazawa T; Okui T; Hassan NM; Honami T; Horikiri Y; Hatakeyama S; Takaoka M; Naomoto Y; Sasaki A
Oral Oncol; 2012 Nov; 48(11):1159-70. PubMed ID: 22766511
[TBL] [Abstract][Full Text] [Related]
11. TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR.
Golubovskaya VM; Virnig C; Cance WG
Mol Carcinog; 2008 Mar; 47(3):222-34. PubMed ID: 17849451
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo.
Ucar DA; Magis AT; He DH; Lawrence NJ; Sebti SM; Kurenova E; Zajac-Kaye M; Zhang J; Hochwald SN
Anticancer Agents Med Chem; 2013 May; 13(4):595-602. PubMed ID: 23272972
[TBL] [Abstract][Full Text] [Related]
13. A novel small molecule inhibitor of FAK and IGF-1R protein interactions decreases growth of human esophageal carcinoma.
Ucar DA; Cox A; He DH; Ostrov DA; Kurenova E; Hochwald SN
Anticancer Agents Med Chem; 2011 Sep; 11(7):629-37. PubMed ID: 21707510
[TBL] [Abstract][Full Text] [Related]
14. Oral administration of FAK inhibitor TAE226 inhibits the progression of peritoneal dissemination of colorectal cancer.
Hao HF; Takaoka M; Bao XH; Wang ZG; Tomono Y; Sakurama K; Ohara T; Fukazawa T; Yamatsuji T; Fujiwara T; Naomoto Y
Biochem Biophys Res Commun; 2012 Jul; 423(4):744-9. PubMed ID: 22705303
[TBL] [Abstract][Full Text] [Related]
15. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
Shi Q; Hjelmeland AB; Keir ST; Song L; Wickman S; Jackson D; Ohmori O; Bigner DD; Friedman HS; Rich JN
Mol Carcinog; 2007 Jun; 46(6):488-96. PubMed ID: 17219439
[TBL] [Abstract][Full Text] [Related]
16. 3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226.
Hehlgans S; Lange I; Eke I; Cordes N
Radiother Oncol; 2009 Sep; 92(3):371-8. PubMed ID: 19729215
[TBL] [Abstract][Full Text] [Related]
17. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.
Golubovskaya VM; Nyberg C; Zheng M; Kweh F; Magis A; Ostrov D; Cance WG
J Med Chem; 2008 Dec; 51(23):7405-16. PubMed ID: 18989950
[TBL] [Abstract][Full Text] [Related]
18. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells.
Liu W; Bloom DA; Cance WG; Kurenova EV; Golubovskaya VM; Hochwald SN
Carcinogenesis; 2008 Jun; 29(6):1096-107. PubMed ID: 18263593
[TBL] [Abstract][Full Text] [Related]
19. Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice.
Kinoshita K; Aono Y; Azuma M; Kishi J; Takezaki A; Kishi M; Makino H; Okazaki H; Uehara H; Izumi K; Sone S; Nishioka Y
Am J Respir Cell Mol Biol; 2013 Oct; 49(4):536-43. PubMed ID: 23642017
[TBL] [Abstract][Full Text] [Related]
20. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
Ji QS; Mulvihill MJ; Rosenfeld-Franklin M; Cooke A; Feng L; Mak G; O'Connor M; Yao Y; Pirritt C; Buck E; Eyzaguirre A; Arnold LD; Gibson NW; Pachter JA
Mol Cancer Ther; 2007 Aug; 6(8):2158-67. PubMed ID: 17671083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
